Subject: A limited quantity of US labelled Pfizer PrZINECARD® (dexrazoxane for injection) in the 250 mg format will be made available for Canadian patients

Dear Customer,

Pfizer Canada, wishes to provide an update regarding the drug shortage situation for PrZINECARD® (dexrazoxane for injection), in the 250 mg format.

In order to mitigate the impact of the current market shortage, a limited quantity of US-labeled Pfizer ZINECARD (lot ADA047B with expiry date 04/30/2021) will be made available to the Canadian market. Ordering restrictions will apply and product will be distributed on an emergency use basis only.

The US-labelled ZINECARD is identical to the Canadian-labelled product, in terms of the actual drug product content and container closure. The differences relate to the language (i.e. English only) and information provided on both the vial label and carton. An example of the vial labels and cartons from both the US and Canada are provided below.

Please note that given the criticality of this product, we will continue to closely monitor the selling patterns during this period and we will adjust our allocation strategy as necessary. We are strongly recommending that clinicians make every effort to reserve supplies for critical care uses only and redistribute stock between sites whenever possible prior to reordering.

Please refer to the table below for some additional information and the availability dates.

<table>
<thead>
<tr>
<th>NDC</th>
<th>NAME</th>
<th>DESCRIPTION</th>
<th>FORMAT</th>
<th>UPC</th>
<th>ALLOCATION</th>
<th>BARCODE</th>
<th>ESTIMATED AVAILABILITY (MM/DD/YYYY)</th>
</tr>
</thead>
</table>

Pfizer understands and regrets the inconvenience that this situation may cause for patients and clinicians. All efforts are being made to minimize the impact of this shortage on the market.

Please note that page 2 has a visual representation of both labels for your convenience.

Please note that this information is reflected in our weekly Product Availability Report (PAR). For the latest updates on product availability, please refer to our Product Availability Report on www.pfizerInjectables.ca.

For all inquiries including, medical information, allocations and general information related to this product please contact 1-800-387-4974.

Sincerely,

Denis Tremblay
Director, Customer Relations
PFIZER CANADA INC.

ZINECARD © Pharmacia Inc. (Dublin/Ohio), owner/Pfizer Canada Inc., Licensee
<table>
<thead>
<tr>
<th>US vial label</th>
<th>Canadian vial label</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="US vial label" /></td>
<td><img src="image2" alt="Canadian vial label" /></td>
</tr>
</tbody>
</table>

**Pharmaceutical Products**

**US carton**

- NDC 0013-8717-62
- Does not indicate concentration (10 mg/mL) following reconstitution
- Not indicated as “Cytotoxic agent”
- Stated “pH of the resultant solution is 1.0 to 3.0”
- Stability information regarding the reconstituted product both at room temperature and refrigerated are indicated.
- Statement for Dosage and Use is “See accompanying prescribing information”.

**Canadian carton**

- DIN 02153432
- Indicates concentration (10 mg/mL) following reconstitution
- Indicated as “Cytotoxic agent”
- pH statement missing from vial label but present on the Canadian carton.
- Stability information regarding the reconstituted product not indicated. The stability information regarding the reconstituted product, refrigerated, is indicated on the Canadian carton. Alternatively, complete stability information, identical to the US vial label, is detailed in the Product Monograph.
- Statement “Do not administer reconstituted solution directly” is not present on Canadian vial, but present on the Canadian carton.
- Statement for usual adult dose is “See Product Monograph for dosage, administration and direction for use.”
- There is no insert in the Canadian carton. Healthcare professionals are encouraged to consult the [www.pfizer.ca](http://www.pfizer.ca) site.